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Abstract: 
This study was designed to develop and test a system to monitor adherence with non-
hormonal oral chemotherapeutic agents using an automated voice response (AVR) 
system plus nursing intervention. Participants received the Symptom Management 
Toolkit then participated in an interview for symptom severity, satisfaction, and beliefs 
about oral agents. Patients received weekly AVR calls, which assessed adherence to 
oral agents and severity of 15 symptoms. Patients who reported adherence of < 100% of 
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prescribed oral agents or symptoms of 4 or greater (0-10 scale) for three consecutive 
weeks, were called by a nurse for assistance with symptom management and 
adherence to oral chemotherapy medications. Following the 8 weekly AVR calls, 
patients participated in a follow up interview and medical record review. Subjects were 
30 oncology patients who were ambulatory and treated at two cancer centers in Midwest 
USA. The results indicate 23.3% non adherence rate to oral chemotherapy medications 
due to symptoms and forgetting to take the medication. An association between 
symptom management and adherence was found. Symptom severity and beliefs about 
medications were not significantly different between adherent and non adherent patients. 
This pilot study demonstrated the ability to accrue patients for a longitudinal trial and 
informed intervention design, while providing guidance for future interventions and 
research studies.    
 
Background 
There are relatively few studies seeking to determine if patient adherence could be 
improved by reducing severity of symptoms and side effects thought to be related to 
certain medications. This pilot study was guided by two questions: 1) Can patients be 
monitored for adherence to oral chemotherapeutic agents and can adherence be 
improved by an Automated Voice Response (AVR) system and an intervention nurse 
where both address symptom management and adherence 2) Can this be demonstrated 
by an observed association between symptom management and improved patient 
adherence?  
 
Objectives 
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The purpose of this study was to determine whether patients with breast, colon, or lung 
cancer, on non-hormonal oral chemotherapeutic agents can be monitored and receive 
interventions for adherence using an AVR system and a nurse intervener.  
 
Methods  
Setting/Sample: Accrual of patients for this pilot occurred at a National Cancer Institute 
Community Clinical Oncology Programs (NCI CCOP) clinical site, and a university based 
cancer clinic, both located in Michigan. Subjects were entered in the study between 
September 2007 and January 2008. Thirty subjects had solid tumor cancer diagnosis 
including breast, colon and lung cancers, and were on non-hormonal oral 
chemotherapeutic agents. Subjects had a touch-tone phone, no hearing deficits that 
interfered with using a telephone, understood English, had no cognitive deficits as 
evaluated by an on-site nurse, were willing to complete eight automated phone contacts 
requesting information on symptom severity and medication adherence, and phone 
contacts for nurse interventions for management of severity of symptoms and adherence 
to oral chemotherapeutic agents, and were not diagnosed with an emotional or 
psychological disorder under the care of a psychiatrist or psychologist. This pilot study 
began with trained nurse recruiters identifying subjects and explaining the study. All 
enrolled subjects received a copy of the Symptom Management Toolkit (SMT) from the 
nurse recruiter, prior to leaving the clinic.  
  
Instruments and Measures  
Symptom Experience Inventory. The cancer symptom inventory, developed by this 
research team, has been used in previous work.2, 3 Fifteen prevalent symptoms 
associated with patients undergoing chemotherapy were examined. Patients were asked 
if, within the past 7 days, they had experienced each symptom (yes/no) and, if so, to rate 
  4 
 
the severity on a 0 to10-point scale of how severe this symptom was and the extent the 
symptom disrupted or caused limitations in their regular daily activities. 
 
Depression. The CESD-20 depression scale is a widely used measure of depressive 
affect for non-psychiatric populations.4,5 This measure has established psychometric 
properties (coefficient alpha  .89).2 
 
Short Form-12.The SF-12 functional ability scale is a widely used measure of an 
individual’s ability to function. This measure has sound psychometric properties (alpha 
.92) in this research. 
  
Utilization and Services. The study focused on the use of increased physician oncology 
visits, hospitalizations, and emergency room visits during the study time period (8 
weeks).  
 
Beliefs About Medications; Satisfaction with Information on Oral Agents. Adherence to 
oral agents is related to patients’ beliefs about the amount of information they have 
received regarding their prescribed oral chemotherapy agent, including actions and 
possible side effects, and with beliefs about concerns and necessity of specific 
medications.6,7 The concerns and necessities subscales to be used were developed 
from social cognitive8 and self-regulatory frameworks and represents potential costs 
associated with symptoms and side effects. 
 
The Satisfaction with Information about Medicines Scale (SIMS)9 evaluates patients’ 
perceptions of the quality of medication information that they have received.  Two 
subscales related to medications were used.  Internal consistency, measured by 
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coefficient alpha for the oncology sample, was .81 and .80 respectively; test-retest 
reliability produced statistically significant correlations over time for each subscale; and 
validity as tested against adherence was significant. 
  
The second set of measures, Beliefs about Medicines Questionnaire (BMQ), assesses 
patients’ beliefs regarding the necessity and concerns about their medications.10 Specific 
items were tested across multiple samples of patients with different diseases. The 
specific “necessity” and “concerns” subscales had internal consistency scores in the mid 
70’s.  Specific necessity correlated highly with adherence levels and concerns subscale 
correlated with poor adherence. This measure, while not tested on cancer patients, has 
strong psychometric properties and taps dimensions specific to the oral agents 
prescribed in this study.   
 
Out-Of-Pocket Costs. At intake and 10 weeks, patients were asked how much they paid 
out-of-pocket (OOP) for their oral chemotherapy agents. These costs were then pro-
rated over the numbers of pills purchased. The cost of the drugs was obtained from the 
pharmacies, and co-pays were determined for each oral agent.  
 
Adherence with Oral Agents. Patient adherence to their oral chemotherapeutic agents 
was measured from multiple perspectives. Medical record audits were performed at the 
time the patient consented, (identify the site of cancer, stage, the name of the oral agent, 
the number of pills prescribed per day, times per day, number of pills per time, and the 
interval between doses) and at the end of the study (change in dose, pills per day 
intervals and dose delays, stoppages and the dates of each). Patient report of 
adherence was obtained from the intake and 10 week interviews and at each of the 8 
AVR calls. During the intake and 10 week interviews, patients were asked to identify the 
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name of their oral agent, number of pills to be taken in AM and PM, and the number of 
days or weeks on and off pills per month or cycle. At each weekly AVR call, the system 
asked for the number of pills the patient took in the past seven days. If the patient 
reported a number different than programmed initially, the nurse intervener was sent an 
email notifying her of a discrepancy.  
 
Specialty and Regular Pharmacy Report. Following the 10-week interview, the patient’s 
pharmacy was contacted with the patient’s permission and a report requested with fill 
and refill information for the oral chemotherapeutic agent(s), specifically detailing the 
number of pills dispensed to the patient during the study.  
 
Calculation of Adherence Measures. The nurse intervener made the following 
comparisons: 1) compared information from intake audit with data collected during the 
intake interview on medications to assess the baseline level of adherence. This note was 
placed in the electronic intervention file for each patient and anchored decisions 
regarding adherence at subsequent calls.  2) Following each weekly call, patients 
reporting pill counts less or more than originally prescribed, received a call from the 
nurse intervener to confirm non-adherence and to provide an intervention when needed. 
If the patient reported a dose adjustment adjusted by the oncologist, then the nurse 
determined the reason for the adjustment and, if it was due to a symptom, assisted the 
patient to manage the symptom. At that point the intervention was logged as symptom 
assistance. 
 
At the end of the 10-week study, the on-site nurse recruiter audited the medical chart, 
recorded dose changes, delays, reductions, stoppages, and toxic side effects and 
provided the audit results to MSU. This information was compared as follows: a) the 
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weekly AVR patient reports of pill counts with the dose from the medical record adjusted 
for delays, interruptions, and stoppages; b) the Intake and 10-week interviews data were 
paired with the record data on dosing and changes as of the date of the interview; c) 
each of these indicators was paired at each time point against the availability of pills to 
the patient based upon the prescriptions filled and number of pills obtained per script. 
The pilot study collected an array of adherence measures for each patient.   
 
Patient Acceptability and Satisfaction. Patient acceptability of the intervention was 
measured by number of AVR calls missed that were not related to hospitalization or poor 
health. Telephone hang-ups were counted and where in the course of the AVR script 
they occurred – symptom management or adherence. Second, acceptability was 
assessed by the proportion of nurse calls that were accepted and completed for 
management of symptoms and for assistance with adherence (nurse-related 
acceptance).  Satisfaction with the AVR system and Symptom Management Toolkit 
(SMT) was measured using a short satisfaction instrument designed especially to 
capture patients’ level of satisfaction with the AVR system that was used in the previous 
RCT.  A series of satisfaction items describing dimensions of patients’ satisfaction with 
the nurse calls were used to examine adherence.  This satisfaction measure was used in 
a previous trial of the AVR.  Psychometrics for this instrument were found to be 
acceptable (alpha greater than .65) as assessed during the course of the pilot study.  
 
Procedures 
The pilot study began with trained nurse recruiters identifying patients and explaining the 
study. All enrolled patients received a copy of the SMT from the nurse recruiter, prior to 
leaving the clinic. Enrolled patients then received an intake interview, eight AVR calls, an 
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exit interview and nurse intervention calls when the AVR system indicated non-
adherence and/or symptom severity of >4 for three consecutive weeks. 
 
Interviews 
Intake and Exit Interviews were conducted by experienced interviewers and entered onto 
a Computer Assisted Telephone Interview system. Sociodemographic information was 
collected on the intake interview. Patient intake and exit interviews included: 
measurements of adherence, compliance with oral medications, oral chemotherapy pill 
beliefs, health conditions, symptoms, the CESD, the SF-12, beliefs, and service 
utilization. 
 
Data were collected at all eight AVR contacts by the investigation software. The AVR 
system used a pleasant female voice that asked to speak when that person would be 
available or the system called two more times at 40 minute intervals and repeated this 
process the following day beginning at the scheduled time. If no one answered on the 
second week, then the project manager contacted the patient directly.  
 
The study patients received eight weekly calls from the AVR System to assess severity 
of 15 symptoms, and oral chemotherapy agent(s) adherence. At each contact, patients 
were asked to enter their personal identity number (PIN) for identification. If incorrect or 
forgotten, then someone from the staff called the patient and reminded them of their PIN 
so that calls could take place. At the first and all subsequent calls, patients were asked 
about the number of oral cancer pills they were prescribed and had actually taken in the 
past week. Then patients were queried as to the severity of each of 15 symptoms; 
asking them to indicate on a scale from 0 (not present) to 10 (worst severity possible), 
“currently how severe is your symptom?”  At the end of the call the system indicated the 
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symptoms that patients identified with a severity of 4 or higher and asked them to read 
those sections of the SMT for each symptom. Subsequent calls began with questions on 
the number of pills taken and then a review of those symptoms scored at a 4 or higher at 
the previous session then followed. Patients were asked: at the last call, you indicated 
(the voice states the symptom) symptom was a problem for you at a moderate or higher 
level; were you able to read the information in the SMT? If yes, how helpful was this 
information for managing this symptom?  
 
Once all symptoms above threshold from the previous call were reviewed and the value 
of the SMT scored, the program asked the current adherence and symptom severity 
questions, severity of current symptoms rated, and the SMT assigned. To this script we 
added questions to patients regarding the numbers of pills they had taken in the past 
week and the number of pills prescribed. If the patient reported anything other than the 
exact number of chemotherapy pills prescribed, a nurse would review the pill count with 
the patient’s prescription and a calendar indicating cycle information which included on-
off days or weeks; and if the count appeared non-adherent the patient was called by the 
nurse to confirm an accurate pill count. Many times during this pilot patients either 
counted their pills incorrectly or pressed the wrong telephone keys. As a final means of 
confirming patient-adherence with the physicians prescribed dosage of oral 
chemotherapy, a medical record audit was conducted including pharmacy fill and refill 
information.  
 
Nursing Interventions 
Study patients reporting symptom severity at their weekly AVR calls were encouraged to 
use the SMT. In addition, if the patient reported anything less than 100% adherence 
through the weekly AVR calls or severity of one or more symptoms at a >4 for three 
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consecutive weeks, a nurse contacted the patient by telephone to confirm non-
adherence and/or provided evidence-based nursing intervention for adherence and/or 
management of symptoms. Preliminary work using the AVR call system was completed 
by the research team comparing a nurse administered telephone intervention to reduce 
symptom severity among advanced cancer patients undergoing chemotherapy (primarily 
infusion). The results of the previous work indicated that both the AVR alone and with 
nursing intervention decreased symptom severity.11,12 
 
Nursing interventions were based on Cognitive Behavioral Theory. The domains for the 
nursing interventions include: fostering self care behaviors, providing information about 
oral agents, problem solving for symptoms or adherence, providing support, coaching 
and counseling, communication with providers, and decision making; all to enhance 
tailored symptom management and adherence behaviors. The nurse intervention 
strategies were evidence-based for each symptom or adherence. Strategies on 
symptoms have been tested in three previous NCI funded RCTs and were used to form 
a plan of care for the patient. Symptom Management Toolkit (SMT) is a supplemental 
information source given to all patients. It is organized into a Frequently Asked 
Questions format and covers what is needed to manage side effects from treatment and 
the sequelae of cancer. Questions include: What is the symptom; How do people 
describe it; What causes it; What do people do to manage it; Where can they find 
additional information; and, Where can they find additional information? This guide has 
been used in several RCT’s and is well accepted by patients. The reading level is 6th-7th 
grade.   
 
Results 
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This pilot study examined the ability to monitor patients for adherence to oral 
chemotherapeutic agents, using an AVR program and a nurse administered telephone 
intervention to reduce symptom severity among advanced cancer patients undergoing 
chemotherapy.  A total of 30 patients agreed to participate in the study, signed informed 
consents and completed the recruitment process. Eight withdrew from the study (26.7%) 
for various reasons (predominately health related).  
  
Sociodemographic Characteristics 
The sociodemographics of the sample are presented in Table 1. The mean age of the 
subjects was 59.93 years (SD = 12.03), and 94% were female. Sixty-three percent of the 
subjects had at least some college education, 90% were white, and 80% were married. 
Breast cancer was the most common diagnosis and 77.67% were on a single oral 
chemotherapeutic agent, with varied lengths of time, from 1 to 8 months. No significant 
differences between the groups at baseline were found for gender, age, race, or 
ethnicity, education, marital status or type of cancer, and in some instances, the sample 
size was too small to test equivalency. 
 
Non-adherence 
The percent of missed pills was calculated weekly using the number of pills confirmed, 
divided by the number of pills prescribed. Seven out of 30 study subjects, or 23%, had 
confirmed non-adherence over the eight week study period. The most common reported 
reason for non-adherence was ‘forgot’ to take the pills, which occurred with 5 subjects. 
One subject could not identify a reason of non-adherence. Six of the non-adherent 
patients missed pills one time out of the 8 weeks, or 13% of the time the subject missed 
their full number of prescribed pills. One patient missed 4 out of 8 weeks, or 50% of the 
time the subject missed their full number of prescribed pills. Of the six subjects who 
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missed pills they took between 86% and 93% of their weekly pills. Of the subject that 
missed pills for 4 out of 8 weeks, the subject reported taking 90% of the prescribed pills 
on average.  
 
Association between Symptom Management and Non-Adherence 
To check the effect of symptom management, we used paired t-test to see how 
symptom severity changed before and after AVR intervention. Sum of symptom severity 
at intake was treated as symptom severity before intervention and at exit as after 
intervention. Overall, for 22 patients who finished intake, AVR intervention and the exit 
interview, their average sum of symptom severity decreased 4.35 with p-value 0.21 
(which means not a significant difference between symptom severity before AVR 
intervention and after AVR intervention). When we compared the symptom severity 
before intervention and after intervention for those who stayed in the pilot study by their 
adherence status, there existed a marginal decrease in severity for non-adherence (p-
value = 0.04) as shown in Table 2.  
 
Association between Number of Oral Agents and Adherence  
To understand if two oral agents influence non-adherence more than one oral agent, a 
comparison was conducted (see Table 3). 77% of the study subjects were on one oral 
agent and 23% were on two oral agents. 17 study subjects, or 57%, were on concurrent 
intravenous chemotherapy. 75% were adherent on single oral agent compared to 86% of 
the subjects who were on two oral agents. In addition, eight study subjects, or 27%, 
discontinued their oral agents sometime during the study. Five study subjects or 17% 
had a physician initiated dosage change (increase or decrease in dosage).  
 
Nurse Interventions 
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During the pilot study, a specialty trained nurse intervener provided patient-centered 
personalized interventions via phone calls for patients that had symptom severity of 4 or 
higher for three consecutive weeks and/or to patients that had non-adherence of less 
than 100%. (See Table 4) 
 
Satisfaction Questionnaires  
Satisfaction questionnaires were administered to all subjects following the 10-week 
survey. 54% of the study subjects completed the satisfaction questionnaire, for a total of 
77% (see Table 5). Of the 17 subjects that completed the satisfaction questionnaire, 12 
subjects, or 70% were adherent, and 5 subjects, or 30% were non-adherent.  
 
Overall, 100% of the subjects who completed the survey were either very satisfied or 
satisfied with the AVR for monitoring symptoms. Of those, 76% used the SMT with a 
high rate of referral to the appropriate section of the toolkit to manage a symptom. Of 
those who were contacted by a study nurse, 65% reported help from the nurse with 
symptoms and 100% reported help from the nurse with non-adherence. In summary, 
60% felt the intervention was helpful, while 30% felt it was both burdensome and helpful, 
and 10% felt it was not helpful. Of those, 88% would recommend the intervention for 
symptom management and 53% for adherent to medications. Of the two subjects who 
were non-adherent and completed the survey, neither felt it was helpful with promoting 
adherence to the oral chemotherapy medication and they were non adherent for reasons 
of forgetting and missing pills. 
 
Discussion 
The primary aim of this study was to determine the feasibility of monitoring and providing 
interventions to patients with breast, colon, or lung cancer on non-hormonal 
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chemotherapeutic agents sing and AVR system and nurse intervener. The results 
support such feasibility, as the system was easy to use, easy to learn, and captured the 
clinical information from patients in their homes.  
 
A majority of patients experienced symptoms that were severe enough to generate 
referral to the SMT and nurse interventions, and non-adherence that prompted nurse 
interventions, as well as an alert to their clinician. Fatigue and pain were the most 
frequently occurring symptoms with symptom severity of >4 for three consecutive weeks. 
Fatigue was a side effect of the oral agents that patients were on while on this study. 
Other less frequent symptoms warranting nurse intervention included lack of appetite, 
numbness and tingling, sleep disturbances and distress, which were also side effects 
from their oral agents (see Table 4). The secondary aims of this study were to determine 
if non-adherence can be defined and measured, to examine the relationship between 
symptom severity and adherence, and to compare and contrast the adherence group 
with the non-adherence group. The data presented here supports that contention.  
 
First, and most importantly, non-adherence was defined and measured. Studies indicate 
that self-report measures, although the most common and easiest to use, have varied 
concordance with other means of measuring adherence. 13 Self-reporting using the AVR 
system with follow-up from a nurse from the study would eliminate some of the inherent 
hesitancy a patient might have in admitting non-adherence to the clinicians that 
prescribed the medication. The patients who reported non-adherence through the AVR 
were confirmed when reported to the nurse. The research oncology nurse reviewed the 
enrollment documents, prior to each patient-call. The enrollment documents included 
oral agent information such as a calendar indicating when the patient was to be and off 
oral agent(s).  The nurse asked each patient that reported non-adherence why they 
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missed their pills and again as is consistent with other studies the most common reason 
for missed doses was forgetting.14 For the patient who reporting ‘out of drug’, we 
confirmed drug unavailability through a pharmacy audit. This appeared to be consistent 
with other studies, where the undersupply of cancer drugs appeared to be as common 
(14%) as the undersupply of other drugs.15      
 
Second, the AVR System was tested and found to work effectively and efficiently. 
Automated telecommunication systems have shown in published studies to improve 
medication adherence 16 however to our knowledge this is the first time the AVR system 
has been used to explore how it might improve adherence to oral chemotherapeutic 
agents with cancer patients. We understand that one study showed that simple 
telephone contacts from the clinician’s office by a non-nurse did not significantly improve 
adherence. 17 However, the structured eight-week AVR system plus individualized 
nursing calls may more closely mirror the published work of Burke 18 and Kim 19  with the 
success of using behavioral interventions for improved  adherence.    
 
Finally, a beginning exploration of the relationship between symptom severity, 
adherence, and beliefs about medications occurred. Addressing the barriers to treatment 
adherence is complex and most likely patients have multiple reasons for non-adherence 
to oral agents. The severity of symptoms from cancer and the side effects of the oral 
agents may be one of the reasons. Studies of cancer and non-cancer diseases indicate 
that patients decrease adherence as symptoms and medication side effects occur. 20 In 
this pilot study, no such effect was observed, most likely due to the small sample size.   
 
Although it was beyond the scope of this pilot to evaluate the effectiveness of the AVR 
system and nurse calls as an intervention to improve adherence to oral 
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chemotherapeutic agents, we did learn from our participants that our calls were 
perceived as ‘caring.’ One patient reported that no one at the clinic ever asked her if she 
was taking her pills and therefore she thought she was taking ‘enough’ although she 
missed four doses over the eight week period. Treatment adherence may be improved if 
clinicians directly ask patients about their adherence, as well as review the importance of 
taking oral medications as directed and the possible effect of adherence on their 
response to treatment.17-19, 21, 22 
 
Future studies on interventions for non-adherence include asking the patient if they are 
taking their pills exactly as prescribed at each office visit. Perhaps this question will elicit 
a similar response to clinicians asking patients about their smoking cessation, where just 
asking the question at each visit will improve the outcome, in this case, improve 
adherence.  
 
The level of satisfaction with and acceptability of the AVR was high. The technique, 
voice, and duration were acceptable to subjects and generally did not pose any technical 
difficulty. The few technical problems that were encountered were resolved in a timely 
fashion. Subjects offered suggestions on ways to expand and enhance the system that 
have already been incorporated into future versions. 
 
With these revisions, the next research step, which has been initiated, is to test the value 
of the AVR symptom assessment and management system in improving adherence to 
oral chemotherapy agents. This study is ongoing and will further evaluate the 
relationship between symptom management and adherence. Before an electronic 
system can be incorporated into clinical care, it is essential to demonstrate that these 
systems are reliable, that they improve care, and that they are cost-effective. 
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Tables/Figures:  
 
Table 1 Sociodemographic Characteristics and Cancer  
 
            Adherence (n=23 or 77%)      Non-adherence (n=7 or 23%)  
Demographic Characteristic       n (%)                      n (%)                       
 
Gender                                                                     
  Male                                                           2 (8.7)                                              -       
  Female                                                     21 (91.3)                           7 (100.0)        
Age 
  21-40                                                          1 (4.4)                -        
41-60                                                        11 (47.8)                               5 (71.4)       
61-70                                                            4 (17.4)   2 (28.6)     
>71                                                              7 (30.4)                   - 
Race or ethnicity  
  White                                                          22 (95.7))                           5 (71.4) 
  Black                                                         1 (4.4)                                     1 (14.3) 
  Asian/Other                                                    -                                            1 (14.3) 
Education  
  High school graduate                            10 (43.5)                               1 (14.4) 
  Some college                                           5 (21.7)                                 3 (42.3) 
  College graduate                                   7 (30.4)                                3 (42.3) 
  Some post college                                1 (4.4)                                  - 
Marital status   
  Never married                                           -                                        2 (8.7) 
  Married                                                    19 (82.6)                         5 (71.4) 
  Divorced/Separated                                      2 (8.7)                              - 
  Widowed                                                        2 (8.7)                           - 
Type of Cancer 
  Breast Cancer                                         17 (74.0)                          7 (100.0) 
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  Colon Cancer                                              3 (13.0)                              - 
  Lung Cancer                                           3 (13.0)                               - 
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Table 2. Summed Severity Scores on Intake and Exit Interviews 
 
     Adherence (n=23 or 77%)     Non-adherence (n=7 or 23%)   T-value   P-value 
                                                                      Mean (SD)                       Mean (SD)                      for group         
Clinical Characteristics           difference   
 
Summed symptom  severity scores 
Intake Interview   25.91 (16.69)  24.57 (15.67)           0.20                      0.85 
Exit Interview                  27.38 (20.14)  14.86 (16.0)    1.42                         0.17 
  
 
SD: standard deviation. 
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Table 3. Oral Agents and Months on Oral Agent(s)  
 
                          Adherence (n=23 or 77%)   Non-adherence (n=7 or 23%)  
      n %                      n %              
         
 
Type of single oral agent 
  Capecitabine (Xeloda)                                             12 (70.6)                                             5 (83.3)                                           
  Cyclophosphamide (Cytoxan)                                   2 (11.8)                                               - 
  Erlotinib (Tarceva)                                                     3 (17.7)                                               - 
  Lapatinib (Tykerb)                                                      -                                                        1 (16.7) 
Type of multiple oral agent  
  Cyclophosphamide+Methotrexate                            2 (33.3)                                               - 
  Capecitabine+Lapatinib                                            4 (66.7)                                             1 (100.0) 
Months on oral agent   
1 month                                                                     8 (38.1)                                            3 (42.9) 
2 months                                                                   5 (23.8)                                            1 (14.3) 
3 months                                                                   1 (4.8)                                                - 
4 months                                                                   1 (4.8)                                                - 
5 months                                                                   2 (9.5)                                                - 
6 months                                                                   3 (14.3)                                            1 (14.3) 
7 months                                                                     -                                                     2 (28.6) 
8 months                                                                   1 (4.8)                                                - 
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Table 4. Number of Patients with Symptoms above Threshold (>=4), AVR Interventions, 
Nurse Interventions, Resolution of Symptom by Adherent and Non-adherent Patients 
 
     Number of   Number of  Number of   Number of   Total Number 
  Patients  Patients  Patients  Patients  of Patients 
  with Symptom with Symptom Referred to  Referred to  with Resolved 
  Severity >=4 at Severity Resolved Nurse               Nurse with   Symptoms by 
  First Contact by 3rd week N  Resolved Symptom  End of Study 
         N (%)  N (%*)          by End of Study   N (%*) 
Symptoms                          N (%**) 
 
Fatigue  12 (40.00) 4 (33.33)  8  2 of 8 (25.00) 6 of 11 (50.00))  
Pain  11 (36.67) 2 (18.18)  9  1 of 9 (11.11) 3  of 11(27.27) 
Pain/redness  11 (36.67) 8 (72.73)  3   1 of 3 (33.33) 9 of 11 (81.82) 
Nausea/vomiting   3 (10.00) 1 (33.33)  2   1 of 2 (50.00) 2 of 3 (66.67) 
Lack of appetite   8 (26.67) 4 (50.00)  4   2 of 4 (50.00) 6 of 8 (75.00) 
Constipation    5 (16.67) 2 (40.00)  3   1 of 3 (33.33) 3 of 5 (60.00) 
Skin rash    6 (20.00) 5 (83.33)  1   1 of 1 (100) 6 of 6 (100) 
Numbness/tingling   9 (30.00) 5 (55.56)  4   1 of 4 (25.00) 6 of 9 (66.67) 
Sleep disturbance   4 (13.33) 0  4   2 of 4 (50.00)  2 of 4 (50.00) 
Sore mouth    5 (16.67) 4 (80.00)  1   0  4 of 5 (80.00) 
Distress    6 (20.00) 2 (33.33)  4   2 of 4 (50.00) 4 of 6 (66.67) 
Dyspnea    3 (10.00) 1 (33.33)  2   0  1 of 3 (33.33)  
Diarrhea    7 (23.33) 4 (57.14)  3   0  4 of 7 (57.14) 
Fever    1 (3.33)  1 (100)  0  0  1 of 1 (100) 
Swelling    4 (13.33) 1 (25.00)  3   1 of 3 (33.33) 2 of 4 (50.00) 
 
  *Percentage based on number of patients with symptoms above threshold at first contact 
** Percentage based on number of patients referred to nurse intervention 
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Table 5. Satisfaction with the AVR, SMT, and Nurse Administered Interventions  
 
             Adherence (n=12 70.58%)  Non-adherence(n=5 29.42%) 
Satisfaction Questions         n (%**)         n (% **)            
         
AVR for monitoring symptoms                                                                        
  Very satisfied                                                     9 (75.00)  1 (20.00)            
  Somewhat satisfied         -   2 (40.00) 
  Just right                                                 3 (25.00)  2 (40.00)  
Use of SMT 
  Yes             9 (75.00)     4 (80.00)                  
  No               3 (25.00)  1 (20.00) 
Telephone referred to appropriate 
Section of SMT  to manage symptom * 
  Strongly agree             2 (16.67)  1 (25.00)                      
  Agree                                                  4 (33.33)  3 (75.00)  
  Neither agree or disagree            3 (25.00)      - 
  Disagree              3 (25.00)      - 
Telephone helped patient be more independent 
for symptom management  * 
  Strongly agree             2 (16.67)     -                           
  Agree                                                   3 (25.00)  2 (50.00) 
  Neither agree or disagree            5 (41.66)  2 (50.00)  
  Disagree              2 (16.67)     - 
The MSU nurse helped with symptoms * 
  Strongly agree             3 (30.00)                           -      
  Agree                                                   3 (30.00)  3 (75.00) 
  Neither agree or disagree            2 (20.00)     - 
  23 
 
  Disagree              2 (20.00)  1 (25.00) 
The MSU nurse helped with adherence * 
  Strongly agree            1 (20.00)                      -      
  Agree                                                  2 (40.00)    - 
  Neither agree or disagree           1 (20.00)     - 
  Disagree                -   2 (100) 
  Strongly disagree            1 (20.00)     - 
Overall AVR and Oral Chemotherapy 
Monitoring system   
  Burdensome              -   2 (40.00) 
  Both burdensome and helpful           5 (41.67)     - 
  Helpful                 7 (58.33)  3 (60.00) 
Recommend AVR to Oncologist to 
Monitor symptoms * 
  Yes                        10 (91.91)  4 (80.00)                     
No                           1 (9.09)    1 (20.00)                 
  
Recommend AVR to Oncologist to 
Remind to take pills    
  Yes              7 (58.33)  2 (40.00)                          
  No              5 (41.67)  3 (60.00) 
 
* Some respondents did not complete the entire survey.   
** Percentage totaled for each adherence and non-adherence group. 
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Key Words: Oral Chemotherapy. Symptom management. Adherence. 
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